תוצאות חיפוש - Adam Gibb
- Showing 1 - 4 results of 4
-
1
Brentuximab vedotin in refractory CD30+ lymphomas: a bridge to allogeneic transplantation in approximately one quarter of patients treated on a Named Patient Programme at a single... מאת Adam Gibb, C. Jones, Adrian Bloor, S. Kulkarni, Tim Illidge, Kim Linton, John Radford
יצא לאור 2012Artigo -
2
Valaciclovir for the suppression of recurrent genital HSV infection: a placebo controlled study of once daily therapy. International Valaciclovir HSV Study Group. מאת R Patel, Neil Bodsworth, P D Woolley, B Peters, Gunhild L. Vejlsgaard, Seppo Saari, Adam Gibb, J. Robinson
יצא לאור 1997Artigo -
3
Valaciclovir versus aciclovir in patient initiated treatment of recurrent genital herpes: a randomised, double blind clinical trial. International Valaciclovir HSV Study Group. מאת Neil Bodsworth, R. J. Crooks, Sueli Donizete Borelli, Gunhild L. Vejlsgaard, Jorma Paavonen, A M Worm, N. Uexkull, Jørgen Esmann, Anders Strand, A.J. Ingamells, Adam Gibb
יצא לאור 1997Artigo -
4
Treatment outcomes in patients with large B‐cell lymphoma after progression to chimeric antigen receptor T‐cell therapy מאת Gloria Iacoboni, Josu Iraola‐Truchuelo, Maeve O’Reilly, Vı́ctor Navarro, Tobias Menne, Mi Kwon, Ana África Martín‐López, Sridhar Chaganti, Javier Delgado, Claire Roddie, Ariadna Pérez, Jane E. Norman, Manuel Guerreiro, Adam Gibb, A Caballero, Caroline Besley, Nuria Martínez‐Cibrián, Alberto Mussetti, Robin Sanderson, Hugo Luzardo, Sunil Iyengar, José María Sánchez, Ceri Jones, Juan‐Manuel Sancho, Pere Barba, Anne‐Louise Latif, Lucía López‐Corral, Rafael Hernani, Juan Luís Reguera, Anna Sureda, Alejandro Martı́n, Mariana Bastos‐Oreiro, Pau Abrisqueta, Andrea Kühnl
יצא לאור 2024Artigo
כלי חיפוש:
נושאים קשורים
Internal medicine
Medicine
Surgery
Aciclovir
Adverse effect
Confidence interval
Hazard ratio
Herpesviridae
Immunology
Lymphoma
Oncology
Valaciclovir
Viral disease
Virus
Alternative medicine
Anaplastic large-cell lymphoma
Antigen
Astrobiology
Autologous stem-cell transplantation
Biology
Brentuximab vedotin
CD30
Cancer research
Chemotherapy
Chimeric antigen receptor
Clinical endpoint
Dermatology
Gastroenterology
Herpes simplex virus
Hodgkin lymphoma